Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy in patients with advanced HER-2 negative gastric or gastroesophageal junction cancers: the ARMANI phase III trialMaria Di Bartolomeo, Filippo Pietrantonio, Maria Antista et al.|BMC Cancer|2019Cited by 15
Randomized phase 3 study of intermittent or continuous Panitumumab plus FOLFIRI for first-line treatment of patients with unresectable left-sided RAS/BRAF wild-type metastatic colorectal cancer: the IMPROVE-2 trialAntonio Avallone, Umberto Malapelle, Alfonso De Stefano et al.|Research Square|2025Cited by 0